Article: Nicotinamide Riboside Supplementation Improves Alzheimer's Biomarkers in Subjective Cognitive Decline and Mild Cognitive Impairment: Clinical Findings

Jan 15, 2025 Alzheimer's Disease Clinical Neurological Health

Nicotinamide Riboside Supplementation Improves Alzheimer's Biomarkers in Subjective Cognitive Decline and Mild Cognitive Impairment: Clinical Findings

Objectives

To test the safety and efficacy of oral NR supplementation on cognition and Alzheimer's disease (AD) blood biomarkers in older adults with subjective cognitive decline and mild cognitive impairment (MCI).

Journal

Alzheimer's & Dementia: Translational Research & Clinical Interventions

Key Outcomes

NR supplementation had no impact on cognition.
NR resulted in a 7% reduction in plasma pTau217 concentrations, a biomarker for AD, while placebo resulted in an 18% increase..

Duration

8 weeks

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, crossover study in 46 older adults with subjective cognitive decline and mild cognitive impairment (MCI)

See Published Study

Cellular Health

NR and Inosine Restore Metabolic Activity in NAXD-Deficient Cells: Preclinical Findings

Synopsis Mutations in the metabolite-repair enzyme NAXD, which normally converts damaged NADHX/NADPHX back into functional cofactors, cause the severe neurometabolic disorder PEBEL2. In human NAXD...

Polycystic Ovary Syndrome (PCOS)

Nicotinamide Riboside Improves Ovarian Function in PCOS: Preclinical Findings

Synopsis In a DHEA-induced mouse model of polycystic ovary syndrome (PCOS), ovarian NAD+ levels dropped sharply, leading to mitochondrial dysfunction in granulosa cells, stromal cells, and oocytes...